Spyre Therapeutics, Inc. (SYRE) Tops Q2 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq climbs over 1% as SpaceX, Super Micro improve AI sentiment
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
Tweet
Share
E-mailGet Alerts SYRE Hot Sheet
Join SI Premium – FREE
Spyre Therapeutics, Inc. (NASDAQ: SYRE) reported Q2 EPS of ($0.86), $0.09 better than the analyst estimate of ($0.95).
For earnings history and earnings-related data on Spyre Therapeutics, Inc. (SYRE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Putin's Aide Says War In Ukraine Moving Toward An End - Vesti
- Raymond James: 'We expect AT&T to focus spectrum acquisitions on fiberheavy areas going forward to support that converged effort.'
- US Treasury Updates Sanctions Related to Iran
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
